Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of AP-101 in ALS
2024-512343-23-00Phase 2Completed
- Sponsor
- AL-S Pharma AG
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of AP-101 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by AL-S Pharma AG. Started May 2024; status: completed.
02
Drugs
AP-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2024-512343-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512343-23-00.